{"pmid": "9003876", "sentences": {"sent_1": {"Section": "METHODS", "text": "Topical beta-blockade with intrinsic sympathomimetic activity offers no advantage for the respiratory and cardiovascular function of elderly people .", "entities": {"entity_1": {"text": "Topical beta-blockade", "class": "Intervention", "negation": 0, "UMLS": "", "start": 0}, "entity_2": {"text": "intrinsic sympathomimetic activity", "class": "Intervention", "negation": 0, "UMLS": "", "start": 3}, "attribute_1": {"text": "advantage", "class": "modifier", "negation": 0, "UMLS": "", "start": 8}, "entity_3": {"text": "respiratory and cardiovascular function", "class": "Outcome", "negation": 0, "UMLS": "", "start": 11}, "entity_4": {"text": "elderly people", "class": "Participant", "negation": 0, "UMLS": "", "start": 16}}, "relations": {}}, "sent_2": {"Section": "METHODS", "text": "Topical therapy with beta-antagonists , such as timolol , may cause unrecognized impairment of respiratory and cardiovascular function in elderly people .", "entities": {}, "relations": {}}, "sent_3": {"Section": "METHODS", "text": "Beta-antagonists with intrinsic sympathomimetic or cardioselective properties , such as carteolol or betaxolol , may cause less impairment .", "entities": {}, "relations": {}}, "sent_4": {"Section": "METHODS", "text": "In a randomized , double-masked study of glaucoma patients , over 60 years of age , without history of bronchospasm and who were using timolol ( 0.5 % ) ,", "entities": {"entity_5": {"text": "glaucoma", "class": "Participant", "negation": 0, "UMLS": "", "start": 7}, "attribute_2": {"text": "over 60 years", "class": "measure", "negation": 0, "UMLS": "", "start": 10}, "entity_6": {"text": "age", "class": "Participant", "negation": 0, "UMLS": "", "start": 14}, "entity_7": {"text": "bronchospasm", "class": "Participant", "negation": 0, "UMLS": "", "start": 19}, "entity_8": {"text": "timolol", "class": "Participant", "negation": 0, "UMLS": "", "start": 24}, "attribute_3": {"text": "0.5 %", "class": "measure", "negation": 0, "UMLS": "", "start": 26}}, "relations": {}}, "sent_5": {"Section": "METHODS", "text": "60 patients were allocated to betaxolol ( 0.5 % ) or carteolol ( 2 % ) or continued timolol ( 0.5 % ) treatment .", "entities": {"entity_9": {"text": "betaxolol", "class": "Intervention", "negation": 0, "UMLS": "", "start": 5}, "attribute_4": {"text": "0.5 %", "class": "measure", "negation": 0, "UMLS": "", "start": 7}, "entity_10": {"text": "carteolol", "class": "Intervention", "negation": 0, "UMLS": "", "start": 11}, "attribute_5": {"text": "2 %", "class": "measure", "negation": 0, "UMLS": "", "start": 13}, "entity_11": {"text": "timolol", "class": "Intervention", "negation": 0, "UMLS": "", "start": 18}, "attribute_6": {"text": "0.5 %", "class": "measure", "negation": 0, "UMLS": "", "start": 20}}, "relations": {}}, "sent_6": {"Section": "METHODS", "text": "Spirometry , pulse and blood pressure were measured on enrollment and after 4 weeks .", "entities": {"entity_12": {"text": "Spirometry", "class": "Outcome", "negation": 0, "UMLS": "", "start": 0}, "entity_13": {"text": "pulse and blood pressure", "class": "Outcome", "negation": 0, "UMLS": "", "start": 2}}, "relations": {}}, "sent_7": {"Section": "METHODS", "text": "In the timolol and carteolol groups there were no significant changes in mean spirometric values .", "entities": {"entity_14": {"text": "timolol", "class": "Intervention", "negation": 0, "UMLS": "", "start": 2}, "entity_15": {"text": "carteolol", "class": "Intervention", "negation": 0, "UMLS": "", "start": 4}, "attribute_7": {"text": "significant changes", "class": "modifier", "negation": 0, "UMLS": "", "start": 9}, "entity_16": {"text": "mean spirometric values", "class": "Outcome", "negation": 0, "UMLS": "", "start": 12}}, "relations": {}}, "sent_8": {"Section": "METHODS", "text": "Changing to betaxolol improved mean peak flow ( PF ) by 9.1 % , from 310 to 3411/min ( p < 0.05 ) and forced expiratory volume in 1 second", "entities": {"entity_17": {"text": "Changing to betaxolol", "class": "Intervention", "negation": 0, "UMLS": "", "start": 0}, "attribute_8": {"text": "improved", "class": "modifier", "negation": 0, "UMLS": "", "start": 3}, "entity_18": {"text": "mean peak flow ( PF )", "class": "Outcome", "negation": 0, "UMLS": "", "start": 4}, "attribute_9": {"text": "9.1 %", "class": "measure", "negation": 0, "UMLS": "", "start": 11}, "attribute_10": {"text": "from 310 to 3411/min ( p", "class": "measure", "negation": 0, "UMLS": "", "start": 14}, "attribute_11": {"text": "0.05 ) and", "class": "measure", "negation": 0, "UMLS": "", "start": 21}, "entity_19": {"text": "volume in 1 second", "class": "Outcome", "negation": 0, "UMLS": "", "start": 26}}, "relations": {}}, "sent_9": {"Section": "METHODS", "text": "( FEV1 ) by 9.4 % , from 1.74 to 1.861 ( p < 0.05 ) .", "entities": {"attribute_12": {"text": "9.4 %", "class": "measure", "negation": 0, "UMLS": "", "start": 4}, "attribute_13": {"text": "from 1.74 to 1.861", "class": "measure", "negation": 0, "UMLS": "", "start": 7}, "attribute_14": {"text": "p < 0.05", "class": "measure", "negation": 0, "UMLS": "", "start": 12}}, "relations": {}}, "sent_10": {"Section": "METHODS", "text": "Differences in the changes in PF and FEV1 between betaxolol and timolol as well as betaxolol and carteolol groups were statistically significant ( p < 0.05 ) .", "entities": {"attribute_15": {"text": "Differences", "class": "modifier", "negation": 0, "UMLS": "", "start": 0}, "entity_20": {"text": "changes in PF and FEV1", "class": "Outcome", "negation": 0, "UMLS": "", "start": 3}, "entity_21": {"text": "betaxolol", "class": "Intervention", "negation": 0, "UMLS": "", "start": 9}, "entity_22": {"text": "timolol", "class": "Intervention", "negation": 0, "UMLS": "", "start": 11}, "entity_23": {"text": "betaxolol", "class": "Intervention", "negation": 0, "UMLS": "", "start": 15}, "entity_24": {"text": "carteolol", "class": "Intervention", "negation": 0, "UMLS": "", "start": 17}, "attribute_16": {"text": "p < 0.05", "class": "measure", "negation": 0, "UMLS": "", "start": 23}}, "relations": {}}, "sent_11": {"Section": "METHODS", "text": "Twenty-one per cent of those allocated to betaxolol showed clinically significant improvement in FEV1 .", "entities": {"attribute_17": {"text": "Twenty-one per cent", "class": "measure", "negation": 0, "UMLS": "", "start": 0}, "entity_25": {"text": "betaxolol", "class": "Intervention", "negation": 0, "UMLS": "", "start": 7}, "attribute_18": {"text": "clinically significant improvement", "class": "modifier", "negation": 0, "UMLS": "", "start": 9}, "entity_26": {"text": "FEV1", "class": "Outcome", "negation": 0, "UMLS": "", "start": 13}}, "relations": {}}, "sent_12": {"Section": "METHODS", "text": "There was no change in pulse or blood pressure when carteolol was substituted for timolol but an increase of 10 beats per minute ( p < 0.05 ) in mean", "entities": {"attribute_19": {"text": "change", "class": "modifier", "negation": 0, "UMLS": "", "start": 3}, "entity_27": {"text": "pulse or blood pressure", "class": "Outcome", "negation": 0, "UMLS": "", "start": 5}, "entity_28": {"text": "carteolol", "class": "Intervention", "negation": 0, "UMLS": "", "start": 10}, "entity_29": {"text": "timolol", "class": "Intervention", "negation": 0, "UMLS": "", "start": 14}, "attribute_20": {"text": "increase", "class": "modifier", "negation": 0, "UMLS": "", "start": 17}, "attribute_21": {"text": "10 beats per minute", "class": "measure", "negation": 0, "UMLS": "", "start": 19}, "attribute_22": {"text": "p < 0.05", "class": "measure", "negation": 0, "UMLS": "", "start": 24}}, "relations": {}}, "sent_13": {"Section": "METHODS", "text": "resting pulse in the betaxolol group .", "entities": {"entity_30": {"text": "resting pulse", "class": "Outcome", "negation": 0, "UMLS": "", "start": 0}, "entity_31": {"text": "betaxolol", "class": "Intervention", "negation": 0, "UMLS": "", "start": 4}}, "relations": {}}, "sent_14": {"Section": "METHODS", "text": "Therapy with cardioselective beta-blockade may offer significant advantages in respiratory function for elderly people with glaucoma over non-selective drugs , even if they have sympathomimetic activity .", "entities": {"entity_32": {"text": "cardioselective beta-blockade", "class": "Intervention", "negation": 0, "UMLS": "", "start": 2}, "attribute_23": {"text": "significant advantages", "class": "modifier", "negation": 0, "UMLS": "", "start": 6}, "entity_33": {"text": "respiratory function", "class": "Outcome", "negation": 0, "UMLS": "", "start": 9}, "entity_34": {"text": "elderly people", "class": "Participant", "negation": 0, "UMLS": "", "start": 12}, "entity_35": {"text": "glaucoma", "class": "Participant", "negation": 0, "UMLS": "", "start": 15}, "entity_36": {"text": "non-selective drugs", "class": "Intervention", "negation": 0, "UMLS": "", "start": 17}, "entity_37": {"text": "sympathomimetic activity", "class": "Outcome", "negation": 0, "UMLS": "", "start": 24}}, "relations": {}}}}